83269-10-7

Usage

InChI:InChI=1/C17H19N5O2/c1-3-24-17(23)21-13-9-12-15(16(18)20-13)22-14(10(2)19-12)11-7-5-4-6-8-11/h4-10,19H,3H2,1-2H3,(H3,18,20,21,23)

Upstream product

• 83269-20-9 ethyl 6-amino-4-<(1-methyl-2-oxo-2-phenylethyl)amino>-5-nitro-2-pyridinecarbamate oxime 
• 83269-21-0 α-aminopropiophenone oxime 
• 6506-86-1 ethyl (6-amino-4-chloro-5-nitropyridin-2-yl)carbamate 
• 83269-09-4 ethyl 6-amino-4-<(1-methyl-2-oxo-2-phenylethyl)amino>-5-nitro-2-pyridinecarbamate 

Downstream Products

• 121572-34-7 benzyl (5-amino-1,2-dihydro-2-methyl-3-phenylpyrido[3,4-b]pyrazin-7-yl)carbamate 
• 121572-32-5 1-methylpropyl (5-amino-1,2-dihydro-2-methyl-3-phenylpyrido[3,4-b]pyrazin-7-yl)carbamate 
• 121572-31-4 5-amino-1,2-dihydro-2-methyl-7-{[(methylamino)carbonyl]amino}-3-phenylpyrido[3,4-b]pyrazine 

Relevant academic research and scientific papers

'(2S)-(5-amino-1,2-dihydro-2-methyl-3-phenylpyrido(3,4-b)pyrazin-7-yl)-carbamic acid, ethyl ester

The (2S)-(-)-isomer of (5-amino-1,2-dihydro-2-methyl-3-phenylpyrido[3,4-b]pyrazin-7-yl)arbamic acid, ethyl ester is significantly more potent than either the (2R)-(+)-isomer or the (R,S)-(±)- racemic mixture in inhibiting mitotic cell division of L1210 leukemia cells. The compound, pharmaceutical compositions containing the compound, and a method of ameliorating cancer diseases in mammals are disclosed.

1,2-Dihydropyrido[3,4-b]pyrazines: Structure-activity relationships

Certain derivatives containing the 1,2-dihydropyrido[3,4-b]pyrazine (1-deaza-7,8-dihydropteridine) ring system are active against experimental neoplasms in mice. The mechanism of action of these agents has r539w1 =4-amino-1-deaza-7,8-dihydro-6-[(N-methyla